Barbier, Liese
Vulto, Arnold G.
Article History
First Online: 2 November 2021
Change Date: 7 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40265-022-01714-2
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: AGV is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund). AGV is involved in consulting, educational work, and speaking engagements, i.e., AbbVie, Accord, Amgen, Biogen, Effik, Pfizer/Hospira, Fresenius-Kabi, Mundipharma, Roche, Novartis, Sandoz, and Boehringer Ingelheim. LB’s research is supported by the KU Leuven and the MABEL Fund. LB has no commercial or financial relationship that could be perceived as a potential conflict of interest. AGV or LB were not involved in the Kurki or Mysler papers.
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: AGV and LB wrote, revised, and approved this commentary.